In the setting of intensive immunosuppression for the management of rejection in solid organ
transplant (SOT) recipients, or graft-versus-host disease (GVHD) in hematopoietic stem cell …

BACKGROUND & AIMS: The relative efficacies of licensed antiviral therapies for treatment-
naive chronic hepatitis B (CHB) infection in randomized controlled trials have not been …

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In
study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for …

Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment‐
naive patients with chronic hepatitis B virus (HBV) infection but experience in …

Peginterferon alfa‐2a results in a sustained response (SR) in a minority of patients with
hepatitis B e antigen (HBeAg)–negative chronic hepatitis B (CHB). This study investigated …

OBJECTIVES: Hepatitis B virus (HBV), hepatitis C virus (HCV), and the human
immunodeficiency virus (HIV) are endemic in Africa. However, hepatitis co-infection rates …

Hepatitis B surface antigen (HBsAg) seroclearance in chronic HBV infection occurs at an
annual incidence of 1–2%. The long-term outcome after HBsAg seroclearance is excellent if …

HBV has evolved a unique life cycle that results in the production of enormous viral loads
during active replication without actually killing the infected cells directly. Two of the key …

BACKGROUND & AIMS: We investigated the long-term efficacy and renal safety of tenofovir
disoproxil fumarate (TDF), administered to patients co-infected with human …

BACKGROUND & AIMS: We compared treatments for patients with chronic hepatitis B virus
(HBV) infection who had an incomplete response to adefovir dipivoxil (ADV). We evaluated …